BeiGene has been cleared to start Chinese trials of its PARP inhibitor BGB-290, one of a portfolio of homegrown drugs that aims to challenge Western dominance…

Bad news for Teva, much-needed good news for the embattled Mylan: The U.S. Patent and Trademark office’s review board struck down two patents on Teva’s new…

EpiPen has buzz. Unfortunately for Mylan, the buzz isn’t good. FiercePharma has been tracking the story for months: Price hikes, marketing tactics, executive…

Fresh off its $14 billion deal for Medivation--and in the midst of considering whether to split in two--Pfizer snapped up a portfolio of high-powered…

Right now, GlaxoSmithKline’s meningitis B vaccine, Bexsero, doesn’t have the key “universal use” endorsement the company wants from the CDC. So it’s spreading…

Mylan has been pummeled by media, consumers, patients, pundits, politicians and even celebrities over charges of jacking up the price for its EpiPen auto…

Pharma ads may be ubiquitous during prime-time TV, but during the Olympic Games in Rio? Not so much. With $1.18 billion spent overall, pharma only accounted…

Amgen was aiming to launch its cholesterol-fighter Repatha quickly in India. But a panel of CV and renal specialists blocked the PCSK9 drug instead.